Citations

Clear

3030 citation(s) found for "Susan, M".

Safety and pharmacokinetics of ONC201 (dordaviprone) administered two consecutive days per week in pediatric patients with H3 K27M-mutant glioma
Odia, Yazmín , Koschmann, Carl , Vitanza, Nicholas A. , Aguilera, Dolly , Daghistani, Doured , Hall, Matthew D. , Khatib, Ziad, Kline, Cassie , MacDonald, Tobey J. , Mueller, Sabine , Faison, Shamia L., Allen, Joshua E. , Naderer, Odin , Ramage, Samuel , McGovern, Susan L. , Khatua, Soumen , Zaky, Wafik , Kline, Cassie , MacDonald, Tobey , Tarapore, Rohinton S , McGovern, Susan Lynne , Gardner, Sharon L , Koschmann, Carl , Hall, Matthew D , Odia, Yazmin , Blank, Peter M K de , Allen, Jeffrey C. , Tarapore, Rohinton S.

Mayo Clinic

Neuro-Oncology | February 24, 2024 | Volume: 26 | Issue: Supplement_2 | Pages: S155-S164

10.1093/neuonc/noae001 | PMID 38400780 Get It

Abstract Background This study evaluated the safety and pharmacokinetics (PK) of oral ONC201 administered twice-weekly on consecutive days (D1D2) in pediatric patients with newly diagnosed DIPG and/or recurrent/refractory H3 K27M glioma. Methods This phase 1 dose-escalation and expansion study included pediatric patients with H3 K27M-mutant glioma and/or DIPG following ≥1 line of therapy (NCT03416530). ONC201 was administered D1D2 at 3 dose levels (DLs; −1, 1, and 2). The actual administered dose within DLs was dependent on weight. Safety was assessed in all DLs; PK analysis was conducted in DL2. Patients receiving once-weekly ONC201 (D1) served as a PK comparator. Results Twelve patients received D1D2 ONC201 (DL1, n = 3; DL1, n = 3; DL2, n = 6); no dose-limiting toxicities or grade ≥3 treatment-related adverse events occurred. PK analyses at DL2 (D1-250 mg, n = 3; D1-625 mg, n = 3; D1D2-250 mg, n = 2; D1D2-625 mg, n = 2) demonstrated variability in Cmax, AUC0–24, and AUC0–48, with comparable exposures across weight groups. No accumulation occurred with D1D2 dosing; the majority of ONC201 cleared before administration of the second dose. Cmax was variable between groups but did not appear to increase with D1D2 dosing. AUC0–48 was greater with D1D2 than once-weekly. Conclusions ONC201 given D1D2 was well tolerated at all DLs and associated with greater AUC0–48.
Patient‐ and proxy‐reported quality of life in advanced dementia with Lewy bodies
Armstrong, Melissa J. , LaBarre, Brian , Sovich, Kaitlin , Maixner, Susan M. , Paulson, Henry L. , Manning, Carol A. , Fields, Julie A. , Lunde, Angela , Forsberg, Leah K. , Taylor, Angela , Paulson, Henry L , LaBarre, Brian , Armstrong, Melissa J , Boeve, Bradley F. , Galvin, James E. , Li, Zhigang

Mayo Clinic

Alzheimer's & Dementia | February 24, 2024 | Volume: 20 | Issue: 4 | Pages: 2719-2730

10.1002/alz.13745 | PMID 38400528 Get It

AbstractINTRODUCTIONLittle is known regarding quality of life (QoL) in dementia with Lewy bodies (DLB), particularly in advanced stages.METHODSDyads of individuals with moderate–advanced DLB and their primary caregivers were recruited from specialty clinics, advocacy organizations, and research registries. The study collected demographics, disease‐related measures, and measures of patient/caregiver experiences.RESULTSThe Quality of Life in Alzheimer's Disease (QoL‐AD) was completed by the person with DLB and the caregiver (proxy) in 61 dyads; 85 dyads had only a proxy‐completed QoL‐AD. Patient‐ and proxy‐reported scores were moderately correlated (r = 0.57, P < 0.0001). Worse patient‐reported QoL correlated with daytime sleepiness, autonomic symptom burden, and behavioral symptoms. Proxy ratings correlated with dementia severity, daytime sleepiness, behavioral symptoms, dependence in activities of daily living, and caregiver experience measures.DISCUSSIONPatient‐ and proxy‐reported quality of life (QoL) should be assessed separately in advanced DLB. Some symptoms associated with QoL have available therapeutic options. Research is needed regarding strategies to optimally improve QoL in DLB.Highlights Patient and proxy quality of life (QoL) ratings had moderate correlation in advanced dementia with Lewy bodies. Daytime sleepiness affected patient‐ and proxy‐reported QoL. Behavioral symptoms affected patient‐ and proxy‐reported QoL. Autonomic symptom burden affected patient‐reported QoL. Dementia severity, dependence, and caregiver experiences affected proxy ratings.
APOPTOSIS EXPRESSION IN CONGENITAL HEPATIC FIBROSIS
El‐Youssef, Mounif, Mu, Yongping , Huang, L., Crawford, Susan E.

Mayo Clinic

Journal of Pediatric Gastroenterology and Nutrition | February 23, 2024 | Volume: 29 | Issue: 4 | Pages: 512-512

10.1002/j.1536-4801.1999.tb02568.x Get It

EXPRESSION OF TGF β1 RECEPTORS I & II IN CONGENITAL HEPATIC FIBROSIS
El‐Youssef, Mounif, Mu, Yuguang , Huang, L., Crawford, Susan E. , Mu, Y.

Mayo Clinic

Journal of Pediatric Gastroenterology and Nutrition | February 23, 2024 | Volume: 29 | Issue: 4 | Pages: 490-490

10.1002/j.1536-4801.1999.tb02502.x Get It

Endoscopic Endonasal Transtuberculum Approach with Stalk Preservation for Resection of Recurrent Craniopharyngioma
Samson, Susan L. , Donaldson, Angela M. , Quiñones‐Hinojosa, Alfredo , Moniz‐Garcia, Diogo , Almeida, João Paulo

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | February 21, 2024 | Volume: 85 | Issue: S 01 | Pages: S1-S398

10.1055/s-0044-1780417 Get It

Silent Corticotroph Adenomas: An Aggressive Tumor Type That Merits Appropriate Preoperative Characterization
Perez‐Vega, Carlos , Sánchez-Garavito, Jesús E. , Ravindran, Krishnan , Chaichana, Kaisorn L. , Quiñones‐Hinojosa, Alfredo , Samson, Susan L. , Almeida, João Paulo

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | February 21, 2024 | Volume: 85 | Issue: S 01 | Pages: S1-S398

10.1055/s-0044-1780164 Get It

MD Anderson Long-Term Experience with Management of Temporal Bone Paragangliomas
Raza, Shaan M. , Hanna, Ehab, Brown, Paul D. , McGovern, Susan L. , Gardner, Adam , Gunn, Gary B., Moreno, Amy C. , Jack, Phan, Rubino, Franco , DeMonte, Franco , Gidley, Paul W. , Nader, Marc‐Elie , Su, Shirley Y. , Hanna, Ehab, Gunn, Gary B., Lee, Anna So Youn

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | February 21, 2024 | Volume: 85 | Issue: S 01 | Pages: S1-S398

10.1055/s-0044-1779986 Get It

Twenty-Four-Hour Discharge following Transsphenoidal Resection of Pituitary Adenomas: Safety and Feasibility of a Pituitary-Center Cohort
Perez‐Vega, Carlos , Sanchez-Garavito, Jesus Emiliano, Ravindran, Krishnan , Donaldson, Angela M. , Olomu, Osarenoma , Chaichana, Kaisorn L. , Quiñones‐Hinojosa, Alfredo , Samson, Susan L. , Almeida, João Paulo

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | February 21, 2024 | Volume: 85 | Issue: S 01 | Pages: S1-S398

10.1055/s-0044-1779974 Get It

Endoscopic Endonasal Resection of the Medial Wall of the Cavernous Sinus: Mayo Clinic Experience and Impact on Pituitary Surgery Outcomes
Garavito, Jesus Emiliano Sanchez, Perez‐Vega, Carlos , Llano, Juan Pablo Navarro Garcia de, Donaldson, Angela M. , Osarenoma, Olomu, Samson, Susan L. , Quiñones‐Hinojosa, Alfredo , Chaichana, Kaisorn L. , Almeida, João Paulo

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | February 21, 2024 | Volume: 85 | Issue: S 01 | Pages: S1-S398

10.1055/s-0044-1779879 Get It

CALGB 80802 (Alliance): Impact of Sorafenib with and without Doxorubicin on Hepatitis C Infection in Patients with Advanced Hepatocellular Carcinoma
Abou‐Alfa, Ghassan K. , Geyer, Susan M. , Nixon, Andrew B. , Innocenti, Federico , Shi, Qian , Kumthekar, Priya , Jacobson, Sawyer , Dika, Imane El , Yaqubie, Amin , Lopez, Juan , Huang, Binhui , Wen, Yujia , Knox, Jennifer J. , Rajdev, Lakshmi , Meyerhardt, Jeffrey A. , El Dika, Imane , Tang, Yi-Wei , Wen, Yujia , Schwartz, Lawrence H , El-Khouiery, Anthony B , Knox, Jennifer J , Rajdev, Lakshmi , Bertagnolli, Monica M , Meyerhardt, Jeffrey A , O'Reilly, Eileen M , Venook, Alan P , Shi, Qian , Abou-Alfa, Ghassan K , Nixon, Andrew B , Tang, Yi‐Wei , Schwartz, Lawrence H. , El-Khoueiry, Anthony B. , Bertagnolli, Monica M. , O’Reilly, Eileen M. , Venook, Alan P.

Mayo Clinic

Cancer Research Communications | February 16, 2024 | Volume: 4 | Issue: 3 | Pages: 682-690

10.1158/2767-9764.crc-22-0516 | PMID 38363156 Get It

Abstract Sorafenib blocks nonstructural protein 5A (NS5A)-recruited c-Raf–mediated hepatitis C virus (HCV) replication and gene expression. Release of Raf-1-Ask-1 dimer and inhibition of Raf-1 via sorafenib putatively differ in the presence or absence of doxorubicin. Cancer and Leukemia Group B (CALGB) 80802 (Alliance) randomized phase III trial of doxorubicin plus sorafenib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC), showed no improvement in median overall survival (OS). Whether HCV viral load impacts therapy and whether any correlation between HCV titers and outcome based on HCV was studied. In patients with HCV, HCV titer levels were evaluated at baseline and at multiple postbaseline timepoints until disease progression or treatment discontinuation. HCV titer levels were evaluated in relation to OS and progression-free survival (PFS). Among 53 patients with baseline HCV data, 12 patients had undetectable HCV (HCV-UN). Postbaseline HCV titer levels did not significantly differ between treatment arms. One patient in each arm went from detectable to HCV-UN with greater than 2 log-fold titer levels reduction. Aside from these 2 HCV-UN patients, HCV titers remained stable on treatment. Patients who had HCV-UN at baseline were 3.5 times more likely to progress and/or die from HCC compared with HCV detectable (HR = 3.51; 95% confidence interval: 1.58–7.78; P = 0.002). HCV titer levels remained unchanged, negating any sorafenib impact onto HCV titer levels. Although an overall negative phase III study, patients treated with doxorubicin plus sorafenib and sorafenib only, on CALGB 80802 had worse PFS if HCV-UN. Higher levels of HCV titers at baseline were associated with significantly improved PFS. Significance: Sorafenib therapy for HCC may impact HCV replication and viral gene expression. In HCV-positive patients accrued to CLAGB 80802 phase III study evaluating the addition of doxorubicin to sorafenib, HCV titer levels were evaluated at baseline and different timepoints. Sorafenib did not impact HCV titer levels. Despite an improved PFS in patients with detectable higher level HCV titers at baseline, no difference in OS was noted.